Table 1.
The clinical characteristics of LMNA mutation carriers.
| LMNA carrier |
Gender (male/female) |
Age (years) |
Mutation | Symptoms | Cardiac medication | Rhythm | PR (upper limit 200 ms) |
QRS (upper limit100 ms) |
q-waves, low r-waves |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 42 | ser143pro | vertigo | ACE-blocker | fa | - | 158 | V1-3 QS |
| 2 | F | 54 | ser143pro | dyspnea extrasystolia |
none | sr | 276 | 124 | no |
| 3 | F | 30 | ser143pro | none | none | sr | 236 | 96 | no |
| 4 | M | 32 | ser143pro | none | none | sr | 176 | 112 | no |
| 5 | M | 18 | ser143pro | palpitation | none | sr | 176 | 96 | no |
| 6 | F | 18 | ser143pro | none | none | sr | 164 | 108 | no |
| 7 | F | 29 | ser143pro | palpitation | none | sr | 182 | 92 | no |
| 8 | M | 39 | T1085Xdeletion | none | none | sr | 322 | 106 | no |
| 9 | M | 25 | ala132pro | paroxysmal flutter |
warfarin, bisoprolol | sr | 176 | 112 | no |
| 10 | F | 52 | ala132pro | extrasystolia | none | sr | 276 | 92 | no |
| 11 | M | 29 | arg190trp | palpitation | none | sr | 160 | 100 | no |
| 12 | F | 32 | arg190trp | palpitation | none | sr | 140 | 84 | no |
| 13 | F | 64 | arg190trp | vertigo | warfarin, bisoprolol, digoxin | fa | - | 84 | Low r-waves V1-4 |
| 14 | M | 58 | arg190trp | dyspnea NYHA 2 |
warfarin, AT-receptor blocker, diuretic, betablocker | sr | 208 | 100 | QS V1 |
| 15 | M | 43 | ser143pro | none | none | sr | 328 | 90 | no |
| 16 | F | 35 | ser143pro | extrasystolia | none | sr | 224 | 76 | no |
| 17 | F | 39 | ser143pro | none | none | sr | 254 | 114 | QS V1-2 |
This table demonstrates patients age, gender, type of lamin A/C mutation, symptoms, medications, heart rhythm and possible abnormalities in ECG (prolonged PR interval, widened QRS complex or presence on q-waves or low t-waves).
NYHA = New York Heart Association classification; sr = sinus rhythm, fa = atrial fibrillation